PG
ALNY icon

PEAK6 Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

PEAK6 Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,752
Closed -$3.32M – 4255
2017
Q4 		$3.27M Buy
25,752
+23,495
+1,041% +$2.95M 0.02% 1074
2017
Q3 		$265K Sell
2,257
-31,309
-93% -$2.67M ﹤0.01% 3058
2017
Q2 		$2.68M Buy
33,566
+15,366
+84% +$982K 0.02% 1118
2017
Q1 		$933K Buy
18,200
+23
+0.1% +$1.06K 0.01% 1740
2016
Q4 		$681K Buy
18,177
+2,185
+14% +$91.5K ﹤0.01% 2219
2016
Q3 		$1.08M Buy
15,992
+2,746
+21% +$194K 0.01% 1708
2016
Q2 		$735K Buy
13,246
+9,463
+250% +$596K 0.01% 2042
2016
Q1 		$237K Buy
+3,783
New +$252K ﹤0.01% 2977
2015
Q4 		– Sell
-26,972
Closed -$2.17M – 4674
2015
Q3 		$2.17M Sell
26,972
-7,507
-22% -$834K 0.01% 1517
2015
Q2 		$4.13M Buy
34,479
+5,333
+18% +$637K 0.02% 953
2015
Q1 		$3.04M Buy
29,146
+9,958
+52% +$1.01M 0.02% 976
2014
Q4 		$1.86M Buy
19,188
+3,739
+24% +$346K 0.01% 1390
2014
Q3 		$1.21M Buy
+15,449
New +$997K 0.01% 1659

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

PEAK6 Group's ALNY Position: Q1 2018 in Review

PEAK6 Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 25,752 shares — an estimated $3.32M sold.

PEAK6 Group first reported a position in ALNY in Q3 2014 and held it in 13 quarters. The position peaked at $4.13M in Q2 2015. 293 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

  • PEAK6 Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • PEAK6 Group sold 25,752 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $3.32M.
  • PEAK6 Group first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 13 quarters.
  • PEAK6 Group's Alnylam Pharmaceuticals position peaked at $4.13M in Q2 2015.
  • 293 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.